Haridwar-based research center, Patanjali, has made a significant breakthrough in the field of Ayurvedic medicine, with their research paper on herbal formulation Renogrit being featured among the top 100 research papers of 2024 in the prestigious “Scientific Reports” journal, part of the “Nature Portfolio” publication. The paper, which has an impact factor of 3.8, is the 5th most-cited journal globally, and has been downloaded 2,568 times, showcasing the growing interest in Ayurvedic medicines as effective remedies for various ailments and as a subject of scientific curiosity. Renogrit, a Patanjali formulation, has demonstrated its potential in not only repairing kidney damage caused by the anti-cancer drug cisplatin, but also alleviating oxidative stress on kidney cells.
The success of Renogrit is seen as a significant step in establishing the scientific credibility of Ayurveda on a global scale. Acharya Balkrishna, a key figure in the development of Renogrit, believes that the formulation’s success is a testament to the potential of combining ancient wisdom with modern scientific parameters, leading to groundbreaking results. This achievement highlights the potential of Ayurveda in providing effective and safe treatments for various health issues, and paves the way for further research and development in the field. The feat is a significant milestone in the journey of Patanjali’s efforts to harness the potential of Ayurveda, and demonstrates the company’s commitment to evidence-based research and innovation. With this breakthrough, Ayurveda is poised to take its place alongside modern medicine as a trusted and effective form of healthcare.